Medi-Span Drug Data Content Sets

Equips healthcare providers with a decision support tool that helps them quickly identify and monitor potential adverse drug reactions, and when necessary, speed corrective action. It provides the:

• Ability to search and retrieve adverse drug effects data for a given drug or specific drug identifier
• Effect type – categorizes nature of the effect (toxic, carcinogenic, etc.)
• Incidence level – describes the frequency of adverse reactions
• Increased incidence – presents medical conditions in which an adverse effect is more likely to occur and may possibly impact the incidence level
• Onset – describes time frame in which the adverse effect is likely to occur (rapid, delayed, etc.)
• Severity level – rates the potential of the adverse reactions to cause harm
• Documentation level – rates the quantity and quality of medical literature that documents each drug's potential adverse effects
• Restriction condition – describes patient populations and medical conditions in which particular adverse drug effects are known to occur
• Special condition – provides information on patient populations or medical conditions especially prone to particular adverse drug effects

• The American Hospital Formulary Service (AHFS) publishes the AHFS Pharmacologic-Therapeutic Classification codes used throughout the healthcare industry as means for drug classification.
• The file provides links between these eight-digit codes and the Medi-Span Generic Product Identifier (GPI) and the National Drug Code with the AHFS code description. This interoperability makes it easier to create therapeutic classification groups.

• Selection of the correct allergen to add to a patient's profile can be time-consuming, as well as confusing, if your entry system is not configured correctly. Brand names, generic names, drug names with salt forms and some drug names without them all need to be entered and built into a list that professionals can quickly and easily use to select appropriate allergens for their patients' records.
• The Allergen picklist file helps make appropriate allergens available for selection in drop-down application menus by simplifying the process of identifying which allergens to display. Our pre-composed lists help save you time when building your system's picklist functionality, and Allergen picklist offerings also include food and environmental allergens that are commonly encountered in medical practice.

• Support your pricing analytics with Medi-Span AWAC which provides both AWAC and Generic Equivalent WAC (GEWAC) pricing with current and up to 12 historical prices.
• We help you by providing a way to determine WAC pricing for a specific NDC when it is unavailable from the manufacturer. You will also receive information necessary to build a WAC-based Price Index for reimbursement rules or payment rules for multiple-source pharmaceutical products.

Making determinations on a drug product's brand or generic status is complex. The Brand Probability solution provides access to data that drives brand-versus-generic product decisions for inclusions on formulary. This solution includes:

• New and existing data sources, including Drug Application Type (NDA, ANDA), CMS Drug Category Code, Multi-source Code, FDA Orange Book Reference Listed Drug and more
• A weighted algorithm to establish a Brand Probability Percent Value for a drug product
• Historical data that enables probability score changes to be tracked over time

This file provides a codified drug dictionary and drug vocabulary for prescription and medication-based over-the-counter products to support users in the Canadian healthcare market. This core drug information database is the foundation for all other Medi-Span content. The drug products included cover a broad spectrum of pharmaceutical drug products, chemicals, OTC products, devices, supplies and related items.

The file provides a name-based drug file containing the following attributes:

• Drug name concepts
• Drug brand name
• Routed drugs
• Dosage forms
• Route
• Drug descriptor
• Drug descriptor by country
• GPI to Generic Dispensable Drug
• GPI to AHFS Codes
• NAPRA Codes
• KDC Names
• AHFS Classification
• Packaging
• Labeler
• Dispensable Drug attribute descriptions

Supports extensive analysis of drug prices over time by providing drug price history, starting at the time the product was first entered into the Medi-Span system by providing all price fields that were included in the Medi-Span Electronic Drug File (MED-File) for National Drug Codes since the early 1980s, specifically:

• Average Wholesale Pricing (AWP)
• Wholesale Acquisition Cost (WAC) on or after January 1, 1993
• Direct Price (DP)
• Centers for Medicare and Medicaid Services Federal Upper Limits (CMS FUL)
• Prices greater than $10,000 for both the package and the unit

With ongoing increases in verification, monitoring, and reporting requirements for controlled substances, this data helps you meet mandatory compliance with U.S. regulations of controlled substances. This file:

• Helps your organization meet mandatory compliance requirements for prescribing, dispensing, and reporting controlled substances at the federal, state, and U.S. territory level
• Assists multi-state organizations in reducing time spent manually researching and monitoring varying compliance requirements across different regions
• Supports development by vendors and self-programmers of rules, applications, and reports to meet the needs of their users
• Enhances prescribing, dispensing, and claims processing by allowing clinicians to use the data and developer applications to determine compliance with federal, state, and U.S. territory regulations
• Supports quality assurance measures by providing the tools to create reports and develop analysis programs around controlled substances

It Provides:

• Federal, state, and U.S. territory level-controlled substance schedules, PDMP, and ARCOS identified at the National Drug Code (NDC) level
• Indicators, including:
  • E-prescribing
  • Refill limit
  • Duration limit
  • Quantity limit
  • Narcotic/non-narcotic designation
  • Narcotics Addiction DEA Number (NADEAN)
  • Prescription Drug Monitoring Program (PDMP)
  • Automation of Reports and Consolidated Orders System (ARCOS)

• Allows systems that use different ingredient or allergen class nomenclature for drug allergies to share data efficiently and effectively
• Minimizes customer impact from layout changes and non-routine postings by the government, simplifying maintenance of this data set
• Allows disparate systems to share drug allergy information defined as ingredients with RxNorm ingredients and FDA UNII codes
• Allows disparate systems to share drug allergy information defined as allergen classes with VA NDF-RT

This file provides:

• Provides bi-directional mappings between the Medi-Span proprietary ingredient concept and the following:
  • RxNorm Ingredients (INs) and Precise Ingredients (PINs)
  • FDA UNII
• Provides bi-directional mappings between the Medi-Span proprietary allergen classes and VA NDF-RT classes
• Includes a representative text description for each RxNorm, FDA UNII, and VA NDF-RT concept

• Helps you save time by eliminating the need to monitor the FDA website for drug status
• Enables reduction of time spent reviewing updates based on layout changes and non-routine postings by the government
• Raises awareness by providing new application approval information prior to FDA website posting

This file provides:

• FDA Application Number
• Application Type (NDA, ANDA, BLA)
• FDA Approval Date
• FDA Therapeutic Equivalence
• Reference Listed Drug Status
• Product Number
• Indicator flag that identifies an NDC as being available in the Medi-Span drug files
• Medi-Span inactive date for NDCs present in the Medi-Span drug file, but inactive
• Manufacturer-reported information in advance of the FDA's website postings

• Enhances clinicians' ability to screen drug doses by considering patient-specific, clinically relevant parameters
• Supports healthcare providers when dosing high acuity drugs with narrow therapeutic ranges
• Accommodates inter-patient variability
• Assists in screening inappropriate dosing and duration of therapy
• Helps healthcare providers avoid potentially life-threatening complications associated with overdosing
• Helps reduce costs related to the treatment of complications associated with under-dosing or overdosing
• Helps improve patient outcomes by enabling receipt of generally accepted dosage and duration of therapy information, particularly in high-risk cases

This database provides:

• Neonatal (specific to postnatal and/or gestational age), pediatric, adult, and geriatric dosing
• Dose data specific to patient weight, creatinine clearance, and BSA
• Dose data specific to route of administration, indication, dose type (e.g., prophylactic, maintenance and single dose), and special conditions (e.g., hepatic insufficiency, concomitant thiazide diuretic therapy, and radiation therapy)
• Dose data ranges to support screening of daily dose, maximum single dose, frequency, duration, and maximum lifetime dose
• Comment text to aid healthcare providers in evaluating dose screening results

• Helps strengthen existing patient safety measures, particularly in high-volume mail-order pharmacies, by verifying products dispensed using mass-fill processes
• Enhances patient education and compliance when provided as a part of patient educational materials
  • Allows drug images to be printed on patient drug education leaflets, helping the patient or caregiver to verify the medication at home
  • Supports pharmacists by helping patients verify the drugs they are prescribed themselves, comparing them against images printed on education materials
• Helps save time by simplifying unknown drug product identification
• Helps protect patients by enabling pharmacists to visually verify that the correct medication is being dispensed

This Database provides content on thousands of prescription and OTC medications, including tablets, capsules, and liquids:

• Drug Images
  • High-resolution images of tablets, capsules, transdermal patches, and other dosage forms in multiple formats (e.g., .jpg, .gif and .bmp)
  • More than 20,800 unique images
  • Data unique to a National Drug Code (NDC) and to specific manufacturers
  • Images for more than 56,600 NDCs
• Drug Imprints
  • Imprints for tablets, capsules, transdermal patches, and other dosage forms
  • Multiple descriptors for a drug, including color, dose form, coating, shape, flavor, and imprint text, among others
  • Imprints for more than 73,800 NDCs
  • Color and shape palettes allow for specialized colors and shapes to map to more commonly recognized colors and shapes

Access the drug information you need even for drugs that are no longer active. With this solution, you receive an extensive list of inactive NDCs, Universal Product Codes (UPCs), and Health Related Item (HRIs)—dating back to the early 1980s—along with their associated inactive dates.

• Assists in identifying the drugs available to treat a specific medical condition in order to:
  • Facilitate adherence to federal drug use standards
  • Identify potential off-label drug uses and drug contraindications associated with inappropriately prescribed medications
• Allows differentiation between labeled and common off-label drug uses
• Helps professionals assess appropriate drug selection, including during e-prescribing
• Helps avoid hospitalizations, physician office visits, drug therapy, lab tests and other costs associated with inappropriate drug selection
• Optimizes therapeutic outcomes by identifying drugs that are typically used in combination with other drugs to manage a condition
• Supports "proxy" medical condition identification, enabling users to infer medical conditions based on drug therapy when other information is unavailable
• Assists in identifying chronic conditions defined by CMS as eligible for MTM services, thus helping to identify eligible patients

This database provides:

• The ability to search and retrieve drugs available to treat a specific medical condition
• Qualifying conditions – defines any additional condition, disease, population, etc., that must be present for a condition to apply
• Identifies if the drug has been approved by the U.S. Food and Drug Administration (FDA) for the indication
• Documentation source – defines the source of the indication
• Documentation level – includes the quality and quantity of supporting information
• Drug acceptance level - helps differentiate between FDA-approved indications, medically recognized unlabeled uses and other known unlabeled uses
• Therapy duration - distinguishes between short-term use and maintenance drugs
• Outcome - specifies the "expected" clinical result subsequent to drug use
• Additional text provided to further describe the drug-to-indication that is not adequately described by one of the defined attributes

• Identifies undesired effects that drugs may potentially have on lab test results
• Screens:
  • Drug-lab test interferences when drugs are prescribed or lab tests are ordered, facilitating clinical lab intervention when needed
  • Lab results for incorrect or misleading values due to drug interferences
• Provides decision support when interpreting lab results and analyzing results, as required by healthcare regulatory standards
• Helps reduce risk by helping to prevent drug-lab conflicts from occurring and supporting appropriate monitoring of patient clinical status
• Helps improve quality of patient care through advanced identification of potentially inappropriate lab test results
• Aids in reducing expenses related to drug invalidation of lab test results

This database provides:

• Drug-lab conflicts differentiated by response, effect, and documentation level
• Lab test reference range in both traditional and International System of Units (SI) measurements
• Parameter names and codes specific to test method and specimen
• Professional and patient synonyms for lab tests
• Cross-referenced Master Parameter Codes to Logical Observation Identifier Names and Codes (LOINC) that support reporting standards and linkage to proprietary lab databases
• Medicare-approved groups of test "panels" that can be retrieved with a single code

The Drug Therapy Monitoring System (DTMS) provides drug interaction and drug allergy clinical decision support content to enable workflow-based screening during order entry by prescribers or pharmacists. DTMS equips healthcare professionals with timely and clinically relevant information on both prescription and OTC medications, positioning them to measurably improve patient outcomes through enhanced drug therapy monitoring.

Features include:

• Drug-drug, drug-food and drug-alcohol interaction screening
• Severity information that clarifies the potential clinical consequences of a drug interaction
• Management information that describes clinical management of a drug interaction
• Documentation level that provides the quantity and quality of information supporting the drug interaction
• Contraindications/avoidance content that provides additional information and screening criteria for drug interactions n Route and schedule of administration specificity for drug interactions to reduce unnecessary interaction alerts
• Drug interactions also identified by ONC/RAND, Pharmacy Quality Alliance, and Arizona Center for Education and Research on Therapeutics (CERT) lists
• Prior Adverse Reaction (PAR) functionality that differentiates between drug allergies and drug cross-sensitivities n Drug allergy screening by allergen class, ingredient, or product
• Referenced text monographs for professionals and patients

Receive timely alerts for potential duplications in drug therapy. This file:

• Supports Drug Utilization Review (DUR)
• Identifies duplications related to ingredients, actions, or indications
• Screens for drug duplications with abuse potential
• Helps improve both clinical and financial outcomes by helping you avoid potentially toxic or unnecessary therapies
• Assists in reducing risks by helping alert you to unintentional drug duplication associated with the combined use of prescription and OTC medications
• Enhances the safety of patients being treated by multiple physicians

It provides:

• Therapeutic duplications for products used for single and multiple therapeutic purposes
• Ingredient duplications for single- and multiple-ingredient products
• OTC medication duplications
• Codes identifying duplication class, be it an ingredient, mechanism of action, or therapeutic indication
• Significance codes to indicate presence of abuse potential
• Duplication Allowance indicator to specify the number of acceptable duplications before providing an alert

• Establish and compare pricing methodologies for state Medicaid and beyond.  
• Saves you time by eliminating manual processing of pricing updates and data output changes from the government, and by delivering NADAC and/or ACA FUL pricing data in one resource  
• Helps you stay current with content updates as often as daily when Centers for Medicare and Medicaid Services (CMS) posts new data 
• Supports a wide range of applications by linking pricing data to National Drug Codes (NDCs) 
• Assists payers/PBMs in considering price points when establishing contracts, particularly those involving state Medicaid  
• Helps retail pharmacies anticipate baseline pricing for state Medicaid programs  

Get access to important drug pricing data from the Centers for Medicare & Medicaid Services (CMS) as soon as the government makes it available. This file:

• Helps save time by
  • Eliminating manual processing of pricing updates and data output changes from the government
  • Delivering NADAC and/or ACA FUL pricing data in one resource
• Helps reduce the risk of errors from manually gathering prices from the CMS website
• Keeps you current with content updates as often as daily when CMS posts new price data
• Assists payers/PBMs in considering price points when establishing contracts, particularly those involving state Medicaid
• Helps retail pharmacies anticipate baseline pricing for state Medicaid programs
• Supports a wide range of applications, as it links pricing data to National Drug Codes (NDCs), allowing the file to be used whether employing Medi-Span drug files or not

It Provides:

• Ability to license ACA FUL pricing, NADAC pricing, or both within your database
• Initial database provides access to current prices and up to 12 weeks of NADAC price history. (Up to 12 weeks of ACA FUL will be available in the database as pricing information evolves)
• ACA FUL data includes two price points:
  • FUL – the monthly value of ACA
  • Weighted Average AMP (Average Manufacturer's Price)
• Content set provides indicators to Medi-Span content to identify if:
  • The NDC is on the Medi-Span drug file
  • The NDC is inactive in the Medi-Span drug file
  • The Medi-Span unit of measure differs from that defined by CMS
• Extrapolates government NADAC and ACA FUL pricing from NDCs with CMS-published data to similar NDCs on the Medi-Span drug file that are not reported by CMS. On average, for every NDC CMS reports, Medi-Span extrapolates to an additional 1-2 NDCs, and those NDCs are readily identified and distinguished from NDCs with CMS-published data

Millions of healthcare workers are exposed to hazardous drugs every year, putting them at increased risk of health and reproductive issues. We provide a streamlined solution to help you identify these drugs in your system and content to help you protect workers from unwanted exposure and comply with USP <800> regulations for safe handling, storage, and more of hazardous drugs.

This file:

• Supports pursuit of compliance with USP <800> standards for safe procedures regarding handling of hazardous drugs, facilities controls, and more. Failure to comply with standards may result in fines for organizations and continued potential risk to healthcare workers and the environment
• Helps healthcare workers efficiently identify hazardous drugs within the workflow and where contact with these drugs can occur
• Supports safe working conditions for healthcare workers, helping you reduce risk of reproductive issues, impact to fetal development, organ damage, and cancer that can be caused by unwanted exposure to hazardous drugs
• Integrates directly into workflow, saving time and valuable resources
• Helps save time and resources by mapping USP-created HazRx® Dataset to Medi-Span proprietary identifiers, promoting interoperability and reducing the burden on your in-house staff

The file provides:

• Relevant drugs mapped from USP data to NDCs and flexible, usable Medi-Span identifiers
• Generic and brand names of hazardous drugs identified on the National Institute for Occupational Safety and Health (NIOSH) list
• Available dosage forms
• RxNorm identifiers and names
• References to the NIOSH tables for each drug
• Activity and formulation
• Flag to determine if a given hazardous drug handling activity qualifies for an assessment of risk vs handling the activity in accordance with USP <800>
• USP <800> handling and precaution information
• Ability to:
  • Create indicators or flags for medications on the NIOSH list
  • Display alerts and accompanying reference instructions for drugs recognized as hazardous by NIOSH
  • Provide reference details on administration/dispensing, handling, storage, and more for NIOSH-listed drugs to help align with USP <800> standards
• Monthly updates of information received from USP

This file provides Healthcare Common Procedure Coding System Codes (HCPCS) as published on the Centers for Medicare and Medicaid Services (CMS) website.

This database contains:

• An extensive listing of all Level II (HCPCS) values, with a subset of fields provided by the CMS website
• A map to an applicable National Drug Code (NDC), Universal Product Code (UPC), or Health Related Item (HRI) Number (for Level II HCPCS that relate to drug products or supplies)
• A mapping indicator to help determine the quantity to submit for the NDC-UPC-HRI on a claim form

• Helps your organization meet mandatory compliance requirements for adopting ICD-10
• Supports development of user applications that seamlessly translate ICD-10 in patient records to Medi-Span proprietary disease/condition/ procedure vocabularies
• Facilitates interoperability for ICD-10
• Provides the flexibility to either remain with your current solutions or update to newer or more advanced Medi-Span offerings

This file provides:

• ICD-10-CM and ICD-10-PCS codes, both formatted and unformatted
• A brief description for each code to assist developers with validating their functionality
• Bi-directional mappings between ICD-10 and Medi-Span Medical Condition Codes or Disease Code

The Centers for Disease Control and Prevention (CDC) developed and maintains tables for both Vaccine Administered (CVX) and Manufacturers of Vaccines (MVX). The use of CVX and MVX codes enables a common terminology between the healthcare professional and immunization registries at a local, state, or national level.

• Helps facilitate healthcare professionals in fulfilling their immunization submission requirements by correlating Medi-Span vocabularies to the CDC's CVX and MVX values
• Allows healthcare professionals that use different nomenclature for vaccines and manufacturers to share data efficiently and effectively
• Minimizes customer impact from layout changes and non-routine postings by the CDC, simplifying maintenance of this data set

The file provides:

• Bi-directional mappings between:
  • Medi-Span proprietary Dispensable Drug Identifier (DDID) and CVX codes
  • National Drug Codes (NDCs) and CVX codes
  • Medi-Span proprietary Labeler Code and MVX codes
• Includes both active and inactive vaccines and manufacturers available in the United States
• Includes a representative text description for each CVX and MVX code

• Provides seamless access to critical drug prescribing information, including dosing, drug interactions, adverse reactions, warnings and precautions
• Presents information concisely in an easy-to-read format suitable for mobile devices or desktop/laptop applications
• Saves time by eliminating the need to exit the workflow to access drug reference information
• Increases efficiency by simplifying drug research
• Helps you reduce prescribing errors
• Supports patient safety by facilitating patient counseling

This module contains:

• Administration and dosage information organized by patient age, route, and specific disease state or medical condition
• Prescription, OTC, and Canadian medications
• Indications for labeled, off-label, and orphan uses
• Adverse reactions organized by body system
• Warnings and precautions for children, pregnant and lactating women, and the elderly, as well as for specific disease states
• Drug interactions
• Black box warnings
• Patient counseling information
• Monographs linked to the Medi-Span Generic Product Identifier (GPI)
• XML-based monographs and accompanying style sheet to transform the content into HTML or other documents

Help improve medication adherence through patient knowledge

• Save professionals time and help increase efficiency with access to patient education directly within the clinical or healthcare business workflow
• Serve a broad range of patients with all 7,400-plus leaflets available in English and Spanish and more than half of those available in 20 languages
• Easily integrate content through various delivery methods for your convenience:
  • HL7-compliant Infobutton
  • Web Services
  • Locally stored datasets (flat files)
  • API
• Help decrease costs with all your patient education materials available in one package, consolidating resources to a single vendor

This file provides:

• 3,500+ adult and pediatric medication leaflets
• 3,900+ disease, condition, procedure, lab test, natural product, discharge instructions, dental, and healthy living leaflets
• Easy-to-read and written at a 5th-to-7th-grade reading level
• Detailed illustrations, when applicable
• Content updated daily when new information is available
• Coded to ICD-9, ICD-10, RxNorm, SNOMED CT and LOINC
• Available in up to 20 languages

Provides reference values and terminology for laboratory tests, diagnostic procedures, and patient physical assessments

• Helps you save time by enabling quick retrieval of groups of tests commonly ordered as "panels" with a single Panel File code

This database provides:

• Lab tests and clinical assessment parameters specific to testing methods and specimens
• In addition to "normal" range values for laboratory tests, also includes "therapeutic" and "toxic" drug ranges specific to age, gender, and gynecologic status
• Master Parameter Codes cross-referenced to LOINC (Logical Observation Identifier Names and Codes, Regenstrief Institute), which supports HL7 Observation ID reporting standards and linkage to proprietary laboratory databases
• Laboratory test reference ranges, expressed in both traditional units and International System of Units (SI)
• Relational design enables file data to be integrated into health information systems using Medi-Span Generic Product Identifier (GPI) drug files

This foundational drug database is the basis for all other Medi-Span content and provides a codified drug dictionary, drug vocabulary, and drug pricing for prescription drugs and medication-based over-the-counter products in the United States.

• For hospitals, retail pharmacies, payers and drug manufacturers, this database:
  • Provides information to support medication prescribing, medication profiling, clinical screening, pricing research and more
  • Simplifies the process of generic product substitutions
  • Helps increase efficiency by providing quick access to pricing information
• Flexible options of MED-File are available to meet your needs. Options include:
  • Basic:
    • Product names, dose form, route of administration, strength, ingredients
    • Proprietary drug identifiers, including Generic Product Identifier (GPI), Drug Descriptor Identifier (DDID), and Generic Product Packaging Code (GPPC)
    • Data Definition Language (DDL) to facilitate table creation during development
  • Clinical:
    • Basic elements, plus drug name concepts at multiple levels of specificity to support clinicians at different stages in their workflow and detailed ingredient level data
  • Pricing:
    • Basic elements, plus unit and package pricing for multiple drug price types including Average Wholesale Price (AWP), Wholesale Acquisition Price (WAC), Direct Price (DP), Centers for Medicare & Medicaid Services, Federal Upper Limit (CMS FUL), Average Average Wholesale Price (AAWP), Generic Equivalent Average Price (GEAP)
  • Complete:
    • A combination of all the elements from the basic, clinical, and pricing options

Avoid constant monitoring of Medicaid Rebate Programs.

• Helps increase efficiency as you can avoid manual monitoring of the Centers for Medicare and Medicaid Services' (CMS) website for updates
• Saves you time by providing the same information published by the government as part of your regular drug file delivery while helping you with layout changes and non-routine postings by the government

In addition to the components provided by CMS, the Medicaid Rebate File also provides the following attributes:

• In Medi-Span DB Flag: indicates if the specific NDC is or is not present in any one of the Medi-Span databases
• Medi-Span Inactive Date: indicates the inactive date of an NDC if it is in the Medi-Span database and has a status of inactive

• Helps save time spent researching and monitoring Medicare reimbursement designations by providing access to Part B and Part D indicators in one consolidated source
• Helps reduce tedious manual updates — the file automatically updates with new NDCs and changes in Medicare status as they become available

This file provides:

• Medicare Type Indicator: Identifies whether drugs are likely to be covered by Part B and/or Part D, supporting MTM services
• Date tracking: All designation of a drug's status under Medicare are dated, enabling users to track the date any changes in status occurred
• Protected Class Indicator: Identifies if a drug is a member of a CMS protected class
• Short-cycle Indicator: Notes which drugs are approved for short-cycle dispensing
• Additional comment text further clarifies a drug's Medicare status, as well as attributes and key information not covered by the file's indicators

• Selecting a diagnosis or medical condition to enter into a patient's medical record or add to their problem list isn't always as simple, clear and efficient as it seems. Poorly maintained home-grown lists or those that lack user-friendly terminology further complicate the process
• The Medical Condition Picklist File provides concise, targeted, user-friendly lists from which to select a patient's disease/condition/diagnosis for addition to the medical record, helping reduce the likelihood for "free text" entries that contain misspellings and/or are not represented in standard disease classification systems
• Enables vendors and self-programmers to offer one or more lists of medical conditions to facilitate the selection and addition of the condition to the patient's diagnosis or problem list
• Provides pharmacogenomics terms to support drug-to-disease contraindication screening based on genetic variation
• Can be deployed for use in a patient portal or other consumer tools
• This file requires the Medical Conditions Master Database file as a companion solution. The Medical Conditions Master Database file helps you build smart picklists with a structured, flexible medication conditions vocabulary

Build smart picklists with a structured, flexible medical conditions vocabulary. This database:

• Enables multiple current and future disease-based clinical databases to be linked to this single-source medical conditions name database
• Promotes interoperability within health information systems by providing cross-references to industry-standard medical condition terminologies, including ICD-9 CM, ICD-10-CM, ICD-10-PCS and SNOMED CT®
• Aids in medical condition profiling
• Permits navigation to and from more specific and generic medical conditions, helping identify related and potentially relevant medical conditions
• Helps lessen false positive alerts due to inactive patient conditions by permitting programmatic deletion of acute medical conditions (e.g., myocardial infarction and infection) from patient disease profiles
• Offers flexibility in consumer-based and professional clinical screening applications by including professional and patient medical condition synonyms
• Assists in identifying chronic conditions defined by CMS as eligible for MTM services, thus helping you identify eligible patients

The database provides:

• Robust multi-parented, multi-tiered hierarchy
• Multiple names for a given medical condition, including:
  • Primary professional
  • Professional synonym
  • Primary patient
  • Patient synonym
• Multiple attributes for each condition, as applicable, including:
  • Duration
  • Age
  • Gender
  • Pregnancy and lactation
  • Condition type

This helps reduce prescribing errors with clinically appropriate medication orders by:

• Helping produce medication orders tailored to individual patient needs
• Assisting in addressing concomitant medical conditions or patient circumstances that can impact appropriate dosing
• Supporting healthcare providers' judgment and decision making
• Helping reduce the risk of prescribing errors
• Helping reduce costs related to the treatment of complications associated with incorrect dosing
• Enhancing patient outcomes by helping you determine tailored, patient-specific dosing based off of standard recommended dosages

It provides:

• Dosing recommendations for all patient segments, including neonates, infants, pediatrics, adults, and geriatrics
• Patient profile parameters, including age, weight, body surface area, renal function measurement, and any applicable concomitant medical conditions
• Route of administration considerations that show any subtle dosing differences that may exist
• Type of dose administered, such as a loading dose or maintenance dose
• Customizable options to reflect specific user preferences and practice environments, including:
  • Rank positions
  • Audience type
  • Dosage type

With proactive monitoring, patients' therapeutic outcomes can be measured, and potential adverse drug effects can be identified. This file provides recommended procedures, lab tests and physical assessments to be performed or reviewed during drug therapy to help improve those outcomes. This file:

• Generates alerts when lab tests should be ordered or when procedures/assessments need to be performed
• Equips doctors with decision support information for drug selection and patient counseling
• Supports caregivers in monitoring drug therapy on an ongoing basis
• Helps reduce adverse drug effects by helping you proactively monitor drug therapy
• Helps improve efficiency by helping you to proactively identify recommended lab tests and procedures

It Provides:

• Recommended lab tests, physical assessments, panels and diagnostic procedures, including initial timing, frequency and duration
• Restrictions that describe a patient population or medical condition to which that parameter only applies
• Special conditions that provide information about a patient population or medical condition to which that parameter especially applies
• Monitoring "protocols" specific to the general population or the long-term care facility

This file helps identify drugs that need surveillance and supports the patients who are taking them.

• Helps quickly identify medications that may require increased surveillance
• Supports development of safety initiatives
• Facilitates compliance with government reporting requirements
• Allows dynamic and efficient programming of safety indicators and support content

This file provides indicators and data in the following categories:

• Monitoring Programs/REMS
• Black Box Warnings (BBW)
• Medication Guides
• Acetaminophen Ingredient
• Pseudoephedrine Ingredient
• Morphine Equivalent Dosing, including milligram morphine equivalent (MME) values
• Tall Man Drug Names

Additionally, the file provides customers with accompanying content that can be used in conjunction with the indicators when programmed accordingly into end-user systems. Supplemental content is available for:

• REMS
• Black Box Warnings
• Medication Guides (when provided to Clinical Drug Information)

Streamline your Medicare reimbursement activities. To support healthcare businesses' Medicare coverage-related decision-making needs, PAL-B v2 provides consolidated access to timely reimbursement information for drugs covered under Medicare Part B, as published by the Centers for Medicare and Medicaid Services (CMS).

This file provides:

• Complete Payment Allowance Limit information from the CMS website
• CMS data supplemented with specific Medi-Span database information
• File is updated when revisions are posted to the CMS website

• Enhances patient safety by aiding clinical decision support
• Identifies drug-related contraindications and precautions due to age, gender, medical condition/disease state, known genetic factors, pregnancy and lactation based on information in patient records
• Helps healthcare providers reduce complications associated with prescribing and dispensing drugs that are potentially contraindicated
• Helps identify alternative drug products with fewer potential conflicts
• Screens to prevent potentially inappropriate drug use in pregnancy and by breast-feeding mothers
• Creates potential for reduction in costs by proactively identifying and avoiding drug-disease conflict

It provides:

• Co-morbidities and additional conditions for which the precaution is known to especially apply
• Placental Transfer and Food and Drug Administration Risk Factors that affect potential fetal risk during pregnancy
• Breast-Feeding Excreted Codes and Breast-Feeding Ratings that help evaluate potential risks to infants when a drug is used by a breast-feeding mother
• Management levels that rank relative significance based on precaution severity and drug necessity and enable filtering of screening results
• Comment text and citations provide additional clarity and reference information to support the precaution information

RxNorm is a non-proprietary drug vocabulary maintained and distributed by the National Library of Medicine. It has been identified as the vocabulary of choice to be incorporated into government systems as they are updated. This file:

• Allows systems that use different drug nomenclatures to share data efficiently and effectively
• Helps you save time by correlating RxNorm terminology to the closest-matching drug concepts within multiple Medi-Span drug vocabularies
• Helps increase efficiency by allowing Medi-Span brand name drug concepts to be mapped to RxNorm concepts (functionality not available in the Unified Medical Language System, or UMLS)
• It Provides mapping between the following Medi-Span drug concepts to the appropriate RxNorm concept:
  • Generic Product Identifier
  • Drug Descriptor ID
  • Drug Name ID

• Helps facilitate more efficient e-prescribing processes between physicians and pharmacies to help promote safer drug dispensing
• Supports transmission of medication allergy information across disparate systems and organizations
• Promotes interoperability and facilitates information exchange between healthcare systems including retail, mail order, and specialty pharmacies; ambulatory/acute care; long-term care EHRs; and more

It Provides:

• Bi-directional mappings between the Medi-Span proprietary allergen concepts and SNOMED CT® substances
• Can be used as a crosswalk to support the transmission of allergy information necessary for e-prescribing

The Standard Drug Identifiers Database enables users to navigate across related drug concepts, providing the terminology needed to identify drugs by:

• Drug name and its associated description, such as Prozac or Fluoxetine HCl
• Routed drug and its associated description, such as Prozac Oral or Fluoxetine HCl Oral
• Dispensable Drug ID (also known as the DDID from the Medi-Span MED-File) and its associated description, such as Prozac Oral Capsule 20MG or Fluoxetine HCl Oral Capsule 20 MG

The Standard Drug Identifiers Database also supports e-prescribing and Computerized Provider Order Entry (CPOE) by providing broad drug concepts that can be used for drug identification and searching.

As a supplemental file to MED-File v2 and other Medi-Span core drug information databases, the Substitution Groups File helps healthcare organizations keep pace with the evolving landscape of biosimilars. It provides information concerning the concepts describing biosimilar drugs and whether they are rated as Interchangeable or Biosimilar, and allows the user to group biosimilar drugs for reporting purposes and show the relationships between originator and reference drugs.

It provides:

• General information concerning drugs that may be classified into groups according to their Medi-Span Generic Product Identifier (GPI)
• More detailed information including associated NDCs, description, rating type, sub-group number, and the reference concept number

This file aids in reducing confusion and risk by:

• Avoiding prohibited abbreviations and acronyms, based on Joint Commission (JC) and Institute for Safe Medication Practices (ISMP) recommendations
• Eliminating "unsafe" abbreviations, including: U (confused with 0), IU (confused with IV) and cc (confused with 00), among others.

The file provides:

• Descriptive names for drugs that MDDB users can customize for display or printing
• Links from National Drug Code and Generic Product Identifier to an associated Drug Descriptor ID (DDID), allowing drugs to be specified either by brand or generic name
• Specifies drug name, route of administration, dose form, strength, and strength unit of measure as individual attributes of the DDID
• Tall Man lettering

This file is used in conjunction with the Master Drug Data Base v2.5 (MDDB). This data is already included within the Medi-Span Electronic Medication File (MED-File). MED-File users do not need this supplemental file.

• The Uniform System of Classification (USC) is a therapeutic classification system created by IMS America and the Pharmaceutical Marketing Research Group
• This system is market-oriented and is unique to the United States
• It allows the audit user to focus more directly on the market segments of interest and creates uniformity of drug classification across the various services enabling direct comparisons between these services
• The USC therapeutic classification system is more specific than the American Hospital Formulary Service (AHFS) therapeutic classification system and less specific than the Medi-Span therapeutic classification system
• This File Provides mappings between the USC therapeutic classification and the Medi-Span proprietary therapeutic classification

• The Warning Label Database provides clear, concise label text that can be printed onto adhesive labels for application on a prescription vial or container as part of the label-generation process.
• The File automates the Auxiliary Labeling Process to Support Patient Safety
  • Easy-to-understand language to help remind patients of essential instructions and warnings
  • Up to five clinically appropriate warning labels per drug
  • Text available in English, Spanish, and Canadian French languages
  • Electronic cross-references to widely distributed preprinted auxiliary label systems and font sources, including: Pharmex, Samuels, Intercon, Architext, Printed Solutions